Big Cypress Acquisition Corp :Sab Biotherapeutics To List On Nasdaq Through Merger With Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform With Demonstrated Utility In Immunotherapy And Rapid Response To Emerging Diseases.Sab Biotherapeutics - Upon Merger Closing, Combined Company Is Expected To Be Listed On Nasdaq.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Combined Co Will Operate As Sab Biotherapeutics,Will Continue To Operate Under Sab Management Team.Sab Biotherapeutics - Upon Closing Of Proposed Deal, Big Cypress Acquisition Corp.'S Samuel J. Reich & Jeffrey G. Spragens To Join Co'S Board.Sab Biotherapeutics - Sab Co-Founder, Current Executive Chairman, Edward Hamilton, Plans To Transition To Board Observer Role While Remaining Active In Co.Sab Biotherapeutics - Proposed Transaction Implies An Enterprise Value For Sab, On A Post-Merger Basis, Of About $325 Million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。